Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.033
Sell
RSI(14)
44.712
Neutral
STOCH(KDJ)(9,3,3)
46.987
Sell
ATR(14)
0.430
Low Volatility
CCI(14)
-9.694
Neutral
Williams %R
52.795
Neutral
TRIX(12,20)
-0.274
Sell
StochRSI(14)
21.767
Sell
ADC Therapeutics SA
ADCT3.387USD
-0.313-8.46%
Market hours （ET）Quotes delayed by 15 min
381.44MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of ADC Therapeutics SA
Currency: USD Updated: 2025-12-22Key Insights
ADC Therapeutics SA's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 82/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ADC Therapeutics SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
8.000
Target Price
+148.45%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ADC Therapeutics SA Highlights
StrengthsRisks
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Growing
The company is in a growing phase, with the latest annual income totaling USD 70.84M.
Undervalued
The company’s latest PE is -2.61, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 72.94M shares, decreasing 0.00% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 7.21K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of ADC Therapeutics SA is 7.47, ranking 112/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 16.43M, representing a year-over-year decrease of 11.03%, while its net profit experienced a year-over-year decrease of 6.83%.
Score
Financials
6.28
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.39
Operational Efficiency
10.00
Growth Potential
6.48
Shareholder Returns
7.19
ADC Therapeutics SA's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of ADC Therapeutics SA is 6.24, ranking 318/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.61, which is -91.87% below the recent high of -0.21 and -24.33% above the recent low of -3.24.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 82/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of ADC Therapeutics SA is 9.00, ranking 20/404 in the Biotechnology & Medical Research industry. The average price target for ADC Therapeutics SA is 8.00, with a high of 10.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
8.000
Target Price
+148.45%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
ADC Therapeutics SA
ADCT
6
CRISPR Therapeutics AG
CRSP
30
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
argenx SE
ARGX
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of ADC Therapeutics SA is 7.43, ranking 119/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.57 and the support level at 2.89, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.794
Sell
MA10
3.913
Sell
MA20
3.968
Sell
MA50
4.085
Sell
MA100
3.735
Sell
MA200
2.988
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of ADC Therapeutics SA is 5.00, ranking 146/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 63.83%, representing a quarter-over-quarter decrease of 16.83%. The largest institutional shareholder is Steven Cohen, holding a total of 8.14M shares, representing 6.57% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Redmile Group, LLC
HPWH TH AG
Prosight Capital
OrbiMed Advisors, LLC
BlackRock Institutional Trust Company, N.A.
Morgan Stanley & Co. LLC
Nantahala Capital Management, LLC
Auven Therapeutics General LP
1
2
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of ADC Therapeutics SA is 3.58, ranking 139/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.95. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.95
VaR
+7.56%
240-Day Maximum Drawdown
+45.00%
240-Day Volatility
+92.44%
Return
Best Daily Return
60 days
+13.60%
120 days
+13.60%
5 years
+63.11%
Worst Daily Return
60 days
-14.13%
120 days
-14.13%
5 years
-36.21%
Sharpe Ratio
60 days
+0.76
120 days
+1.29
5 years
+0.06
Risk Assessment
Maximum Drawdown
240 days
+45.00%
3 years
+89.46%
5 years
+98.51%
Return-to-Drawdown Ratio
240 days
+1.89
3 years
-0.06
5 years
-0.17
Skewness
240 days
+1.47
3 years
+2.27
5 years
+2.11
Volatility
Realised Volatility
240 days
+92.44%
5 years
+95.14%
Standardised True Range
240 days
+5.79%
5 years
+14.64%
Downside Risk-Adjusted Return
120 days
+209.90%
240 days
+209.90%
Maximum Daily Upside Volatility
60 days
+56.81%
Maximum Daily Downside Volatility
60 days
+84.21%
Liquidity
Average Turnover Rate
60 days
+0.76%
120 days
+0.63%
5 years
--
Turnover Deviation
20 days
-2.78%
60 days
+7.42%
120 days
-10.67%
Peer Comparison
Biotechnology & Medical Research
ADC Therapeutics SA
ADCT
6.95 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of ADC Therapeutics SA?
The TradingKey Stock Score provides a comprehensive assessment of ADC Therapeutics SA based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of ADC Therapeutics SA’s performance and outlook.
How do we generate the financial health score of ADC Therapeutics SA?
To generate the financial health score of ADC Therapeutics SA, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects ADC Therapeutics SA's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of ADC Therapeutics SA.
How do we generate the company valuation score of ADC Therapeutics SA?
To generate the company valuation score of ADC Therapeutics SA, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare ADC Therapeutics SA’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of ADC Therapeutics SA’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of ADC Therapeutics SA.
How do we generate the earnings forecast score of ADC Therapeutics SA?
To calculate the earnings forecast score of ADC Therapeutics SA, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on ADC Therapeutics SA’s future.
How do we generate the price momentum score of ADC Therapeutics SA?
When generating the price momentum score for ADC Therapeutics SA, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of ADC Therapeutics SA’s prices. A higher score indicates a more stable short-term price trend for ADC Therapeutics SA.
How do we generate the institutional confidence score of ADC Therapeutics SA?
To generate the institutional confidence score of ADC Therapeutics SA, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about ADC Therapeutics SA’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of ADC Therapeutics SA.
How do we generate the risk management score of ADC Therapeutics SA?
To assess the risk management score of ADC Therapeutics SA, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of ADC Therapeutics SA’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of ADC Therapeutics SA.
